Grifols, S.A. (GRFS)

Market Cap	5.97B
Revenue (ttm)	7.32B
Net Income (ttm)	65.91M
Shares Out	824.46M
EPS (ttm)	0.10
PE Ratio	72.40
Forward PE	14.88
Dividend	n/a
Ex-Dividend Date	n/a

Volume	455,100
Open	7.39
Previous Close	7.51
Day's Range	7.23 - 7.39
52-Week Range	5.30 - 12.15
Beta	0.67
Analysts	Sell
Price Target	10.50 (+45.03%)
Earnings Date	Jul 28, 2022

About GRFS

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: May 17, 2006
• Employees: 23,737
• Stock Exchange: NASDAQ
• Ticker Symbol: GRFS

Financial Performance

In 2023, Grifols's revenue was 6.59 billion, an increase of 8.71% compared to the previous year's 6.06 billion. Earnings were 59.32 million, a decrease of -71.52%.

Financial numbers in EUR

Analyst Forecast

According to 2 analysts, the average rating for GRFS stock is "Sell." The 12-month stock price forecast is $10.5, which is an increase of 45.03% from the latest price.

Price Target

$10.5

(45.03% upside)

Analyst Consensus: Sell